Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8339214 | 0.86 | LMNA (0.40) | LMNAKDM4ECYP3A4ALDH1A1TP53 | |
| SCHEMBL597046 | 0.82 | NLRP3 (0.50) | NLRP3LMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL28597231 | 0.80 | LMNA (0.34) | LMNACA1CA2 | |
| SCHEMBL28593106 | 0.78 | LMNA (0.33) | LMNA | |
| SCHEMBL28602486 | 0.78 | LMNA (0.33) | LMNA | |
| SCHEMBL11695951 | 0.73 | LMNA (0.45) | NLRP3LMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL29145538 | 0.73 | LMNA (0.39) | NLRP3LMNAALDH1A1CA1CA2 | |
| SCHEMBL23343716 | 0.72 | NLRP3 (0.43) | NLRP3LMNAKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL442185 | 0.72 | — | — | |
| SCHEMBL78146 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9006189-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006189-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-8278281-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278281-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | BioVersys AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | BioVersys AG (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | IL33, PROKR1, PGC | NLRP3 1516/4885LMNA 2134/4885KDM4E 4210/4885 |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | NLRP3 1521/4885LMNA 2995/4885KDM4E 4532/4885 |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | NLRP3 1521/4885LMNA 2995/4885KDM4E 4532/4885 |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | NLRP3 1521/4885LMNA 2995/4885KDM4E 4532/4885 |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | NLRP3 1521/4885LMNA 2995/4885KDM4E 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.